Abivax launches IPO to fund novel AIDS drug
This article was originally published in Scrip
Executive Summary
French vaccines and antiviral firm Abivax has launched its initial public offering on Euronext Paris. It is aiming to raise around €50m to fund Phase IIb studies of its small molecule ABX464, which takes a novel approach inhibiting HIV replication, as well as to continue development of ABX203, a Phase IIb/III therapeutic vaccine against chronic hepatitis B.